SVASTEK, an innovative medtech startup addressing critical challenges in respiratory and critical care, has raised ₹2 crore in seed funding from the IAN Angel Fund. This funding will drive the launch of SVASTEK’s flagship product, the ALLTIP technology-enabled NIV mask, and support the company’s vision to bring impactful solutions to the healthcare industry.
The funds raised will be utilized to launch the ALLTIP-enabled NIV mask across India, build a robust distributor network for seamless product availability, expand SVASTEK’s clinical application team to educate and train healthcare professionals and drive awareness through medical conferences and targeted outreach programs. The ALLTIP NIV mask represents a significant advancement in non-invasive ventilation technology by enabling continuous respiratory support while allowing simultaneous nutrition delivery. This solution addresses a key challenge in clinical settings, ensuring that patients’ respiratory and nutritional needs are managed efficiently without interruptions.
Headquartered in New Delhi, with a production facility at Andhra MedTech Zone in Vishakhapatnam, SVASTEK is well-positioned to contribute to India’s “Make in India” initiative by offering homegrown solutions tailored to the country’s healthcare needs.
Arita Abrol, Founder, SVASTEK, said, “We’re incredibly excited to have closed this round —it’s a huge step forward for SVASTEK. This investment isn’t just about capital; it’s a validation of the vision we’ve been building toward: creating impactful, innovative solutions that transform MedTech globally.
These funds will allow us to expand our team, push the boundaries of innovation, and establish ourselves in this rapidly evolving industry. India is at the cusp of MedTech innovation, and various new initiatives like MedTech Mitra, BIRAC grants, Make in India & ICMR research projects have recently been introduced. The potential here is immense, and we are just scratching the surface of what’s possible. I’m deeply grateful to our investors for believing in this journey, and I can’t wait to see how SVASTEK continues to shape the future of healthcare.”
Padmaja Ruparel, Co-founder, IAN Group, said “SVASTEK’s revolutionary ALLTIP-enabled NIV mask, which impacts critical respiratory issues. IAN is delighted parter with the founders to build a business which will promises to bring a critical care solution to India’s healthcare industry”
The respiratory and critical care market in India is valued at ₹48,500 crores and growing at a CAGR of 8.3%. SVASTEK’s innovative solutions are uniquely positioned to address this burgeoning market, particularly within the ₹5,000 crore segment of masks, consumables, and oxygen devices.
With plans to expand its product portfolio and geographical footprint, the company aims to establish itself as a global leader in respiratory care, driving innovation, affordability, and accessibility in healthcare.